These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3582057)

  • 1. [Basic experiment on the action of isobutol in tuberculosis].
    Gao DZ
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1986 Dec; 9(6):356-8, 383. PubMed ID: 3582057
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
    Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mode of action of antituberculous agents and ultrastructure of mycobacteria.
    Oka S; Yamaguchi J; Ariji F; Madokoro K; Kumano N
    Sci Rep Res Inst Tohoku Univ Med; 1971 Jul; 18(1):7-13. PubMed ID: 5005200
    [No Abstract]   [Full Text] [Related]  

  • 4. The "in vitro" activity of rifampicin compared with ethambutol, capreomycin and isoniazid.
    Steinbrück PW
    Acta Tuberc Pneumol Belg; 1969; 60(3):413-6. PubMed ID: 4984421
    [No Abstract]   [Full Text] [Related]  

  • 5. Studies on atypical mycobacteria. X. Experimental approach to the etiology of atypical mycobacteriosis.
    Ogawa T; Motomura K
    Kekkaku; 1971 Sep; 46(9):365-70. PubMed ID: 5122006
    [No Abstract]   [Full Text] [Related]  

  • 6. [Therapy of tuberculosis].
    Schmidt W
    Hippokrates; 1972 Dec; 43(4):487-9. PubMed ID: 4657130
    [No Abstract]   [Full Text] [Related]  

  • 7. [Activity of the second-line preparations, ethambutol and rifampin, in experimental tuberculosis caused by Mycobacterium tuberculosis highly resistant to basic tuberculostatics].
    Golyshevskaia VI; El'shanskaia MP
    Probl Tuberk; 1973; 51(12):60-4. PubMed ID: 4205666
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
    Hearn MJ; Cynamon MH
    Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 10. [Testing Mycobacterium tuberculosis for drug sensitivity using different methods].
    Skriagina EM; Zalutskaia OM; Roth A; Mauch H; Nikolenko EN
    Probl Tuberk; 2001; (5):43-5. PubMed ID: 11588962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapeutic properties of the alkaloid tetrandrin in experimental tuberculosis].
    Vichkanova SA; Makarova LV; Solov'eva LF
    Farmakol Toksikol; 1973; 36(1):74-8. PubMed ID: 4734361
    [No Abstract]   [Full Text] [Related]  

  • 12. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
    Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current status of the antitubercular chemotherapy].
    Radenbach KL
    Internist (Berl); 1973 Mar; 14(3):100-10. PubMed ID: 4573242
    [No Abstract]   [Full Text] [Related]  

  • 15. [Proceedings: Tuberculosis therapy. Review on today's knowledge, developmental trends and still open problems].
    Eule H; Krebs A; Iwainsky H
    Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):78-100. PubMed ID: 4131870
    [No Abstract]   [Full Text] [Related]  

  • 16. [Progress in the treatment of tuberculosis. Isoniazid plus rifomycin plus myambutol equals standard therapy].
    Freerksen E
    Dtsch Med Wochenschr; 1970 Jan; 95(3):139-41. PubMed ID: 5411222
    [No Abstract]   [Full Text] [Related]  

  • 17. [Experimental study of rifampicin and ethambutol].
    Kozulitsyna TI; Korotaev GA
    Probl Tuberk; 1971; 49(1):64-8. PubMed ID: 5576515
    [No Abstract]   [Full Text] [Related]  

  • 18. [Significance of isoniazid for the therapy of experimental infection with total INH- and SM- resistant human tuberculosis bacteria in the mice].
    Matsumiya T; Freerksen E; Rosenfeld M
    Jpn J Tuberc Chest Dis; 1970 Jul; 16(1):14-29. PubMed ID: 4320557
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
    Lu T; Drlica K
    J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of initial drug resistance to M. tuberculosis in new sputum positive RNTCP patients.
    Dhingra VK; Rajpal S; Bhalla P; Yadav A; Jain SK; Hanif M
    J Commun Dis; 2003 Jun; 35(2):82-9. PubMed ID: 15562953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.